glp-1 agonists australia The RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025 Weight loss drugs Australia: Half

Visceral adiposity is metabolically active and drives insulin resistance, inflammation, and cardiovascular risk in ways that subcutaneous fat does not to the same degree

Skin concerns: Dark spots, post-acne marks, uneven tone, elasticity loss, and dullness

One large electronic database study showed there was a significantly increased risk of diabetic macular edema following GLP-1RA initiation compared to sodium-glucose cotransporter 2 inhibitors (SGLT2i)

Many emerging peptides are accessible to licensed healthcare providers through regulated compounding pharmacies

Among bioactive peptides, GHK Cu peptide (glycyl-L-histidyl-L-lysine-copper) has experienced a surge of interest in both consumer products and scientific literature